Ayala Pharmaceuticals, Inc. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q3 2013 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Ayala Pharmaceuticals, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q3 2013 to Q4 2023.
  • Ayala Pharmaceuticals, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending December 31, 2023 was -$197M, a 32.2% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 -$197M -$48.1M -32.2% Dec 31, 2023 10-K 2024-04-16
Q3 2023 -$173M +$270M +61% Sep 30, 2023 10-Q 2023-11-20
Q2 2023 -$165M +$273M +62.3% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$157M +$275M +63.7% Mar 31, 2023 10-Q 2023-05-23
Q4 2022 -$149M +$280M +65.2% Dec 31, 2022 10-K 2024-04-16
Q3 2022 -$443M -$14.4M -3.35% Oct 31, 2022 10-K 2023-02-10
Q2 2022 -$438M -$15.2M -3.6% Jul 31, 2022 10-Q 2022-09-13
Q1 2022 -$431M -$11.6M -2.76% Apr 30, 2022 10-Q 2022-06-08
Q4 2021 -$429M -$14.3M -3.44% Jan 31, 2022 10-Q 2022-03-17
Q3 2021 -$429M -$17.9M -4.35% Oct 31, 2021 10-K 2023-02-10
Q2 2021 -$423M -$18.9M -4.67% Jul 31, 2021 10-Q 2021-09-10
Q1 2021 -$420M -$21.4M -5.36% Apr 30, 2021 10-Q 2021-06-14
Q4 2020 -$415M -$22.6M -5.76% Jan 31, 2021 10-Q 2021-03-16
Q3 2020 -$411M -$26.5M -6.89% Oct 31, 2020 10-K 2022-02-14
Q2 2020 -$404M -$30.2M -8.07% Jul 31, 2020 10-Q 2020-09-10
Q1 2020 -$398M -$34.2M -9.4% Apr 30, 2020 10-Q 2020-06-11
Q4 2019 -$392M -$37.3M -10.5% Jan 31, 2020 10-Q 2020-03-13
Q3 2019 -$384M -$16.6M -4.52% Oct 31, 2019 10-K 2021-01-22
Q2 2019 -$374M -$25M -7.17% Jul 31, 2019 10-Q 2019-09-09
Q1 2019 -$364M -$29.2M -8.71% Apr 30, 2019 10-Q 2019-06-10
Q4 2018 -$355M -$33.2M -10.3% Jan 31, 2019 10-Q 2019-03-12
Q3 2018 -$368M -$66.5M -22.1% Oct 31, 2018 10-K 2019-12-20
Q2 2018 -$349M -$71.2M -25.6% Jul 31, 2018 10-Q 2018-09-10
Q1 2018 -$335M -$89.8M -36.6% Apr 30, 2018 10-Q 2018-06-07
Q4 2017 -$322M -$96.8M -43.1% Jan 31, 2018 10-Q 2018-03-12
Q3 2017 -$301M -$93.4M -45% Oct 31, 2017 10-K 2019-01-11
Q2 2017 -$278M -$91.9M -49.4% Jul 31, 2017 10-Q 2017-09-11
Q1 2017 -$245M -$75.7M -44.7% Apr 30, 2017 10-Q 2017-06-06
Q4 2016 -$225M -$70.9M -46.1% Jan 31, 2017 10-Q 2017-03-10
Q3 2016 -$208M -$73.7M -54.9% Oct 31, 2016 10-K 2017-12-21
Q2 2016 -$186M -$64.6M -53.2% Jul 31, 2016 10-Q 2016-09-08
Q1 2016 -$170M -$61.6M -57.1% Apr 30, 2016 10-Q 2016-06-08
Q4 2015 -$154M -$59.9M -63.7% Jan 31, 2016 10-Q 2016-02-26
Q3 2015 -$134M -$47.1M -54.1% Oct 31, 2015 10-K 2017-01-09
Q2 2015 -$121M -$37.7M -45% Jul 31, 2015 10-Q 2015-09-11
Q1 2015 -$108M -$29.9M -38.4% Apr 30, 2015 10-Q 2015-06-15
Q4 2014 -$94M Jan 31, 2015 10-Q 2015-03-13
Q3 2014 -$87M -$16.5M -23.5% Oct 31, 2014 10-K 2016-01-08
Q2 2014 -$83.7M Jul 31, 2014 10-Q 2014-09-09
Q1 2014 -$78M Apr 30, 2014 10-Q 2014-06-10
Q3 2013 -$70.5M Oct 31, 2013 10-K 2015-01-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.